---
layout: default
title: Umeclidinium
parent: 僅模型預測 (L5)
nav_order: 707
evidence_level: L5
indication_count: 10
---

# Umeclidinium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Umeclidinium: From Chronic Obstructive Pulmonary Disease to Migraine Disorder

## One-Sentence Summary

Umeclidinium is a long-acting muscarinic antagonist (LAMA) inhaler, most commonly used as part of maintenance therapy for chronic obstructive pulmonary disease (COPD) — this is inferred from the supporting literature in this evidence pack, as no confirmed original indication or Australian regulatory record is currently available. The TxGNN model's top prediction is **Migraine Disorder**, but this is currently supported by **0 clinical trials** and **0 publications**, and the model's own rationale notes there is no known pharmacological mechanism linking antimuscarinic activity to migraine pathophysiology — this appears to be a pure knowledge-graph similarity signal rather than a pharmacologically grounded hypothesis.

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Chronic Obstructive Pulmonary Disease (COPD) — inferred from supporting literature; not confirmed by regulatory data in this evidence pack |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 96.36% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the supporting literature that was returned, umeclidinium is known to be a long-acting muscarinic antagonist (LAMA) delivered by inhalation, typically used within combination COPD maintenance regimens (e.g. with vilanterol, or with fluticasone furoate and vilanterol).

For the top-ranked prediction, migraine disorder, the evidence pack's own mechanistic assessment is explicit: **there is no known antimuscarinic mechanism directly relevant to migraine pathophysiology**, and the signal is described as a pure knowledge-graph comorbidity/embedding similarity prediction without pharmacological support. This should be disclosed transparently rather than reverse-engineered into a plausible-sounding story — the honest interpretation is that this candidate likely reflects model noise rather than a genuine repurposing opportunity.

It is worth noting that lower-ranked candidates in this same evidence pack — gastroduodenitis, common cold, and peptic ulcer disease — carry somewhat stronger (though still indirect) support, based on historical use of other antimuscarinic agents (pirenzepine, ipratropium) in analogous conditions. These were scored at decision stage S1 ("Research Question") rather than S0 ("Hold"), and may warrant closer follow-up ahead of the migraine signal.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Australia Market Information

No ARTG entries were found for umeclidinium in this evidence pack, and market status is recorded as **Not Marketed** in Australia. No product, dosage form, or approved indication data is currently available to report.

## Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack, and the absence of TGA/PI warning data has been flagged as a **Blocking** data gap (DG001) that prevents a full safety pre-assessment.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (migraine disorder) has no supporting clinical trials or literature, and the model's own mechanistic rationale explicitly states there is no known pharmacological link — this is evidence level L5 and should not proceed further as currently framed. Separately, umeclidinium is not marketed in Australia, and safety data (warnings/contraindications) is blocked pending TFDA/TGA product information retrieval.

**To proceed, the following is needed:**
- Retrieve TGA-approved Product Information (warnings, contraindications) to resolve the Blocking gap (DG001)
- Confirm mechanism of action via DrugBank to resolve the High-severity gap (DG002)
- Confirm the drug's actual original indication and regulatory history, since `original_indications` is currently empty in the source data
- If pursuing repurposing further, prioritise the S1 "Research Question" candidates (gastroduodenitis, common cold, peptic ulcer disease) over the migraine signal, and seek preclinical or mechanistic studies specific to umeclidinium rather than relying on same-class drug analogies alone
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

